GSA Capital Partners LLP lowered its stake in shares of Biomea Fusion, Inc. (NASDAQ:BMEA – Free Report) by 36.8% during the third quarter, according to the company in its most recent disclosure with ...

Having said that, unprofitable companies are risky because they could potentially burn through all their cash and become distressed. So, the natural question for Biomea Fusion (NASDAQ:BMEA) ...

Biomea Fusion, Inc. (NASDAQ:BMEA – Free Report) – Investment analysts at HC Wainwright lifted their FY2024 earnings estimates for shares of Biomea Fusion in a research note issued on Thursday ...

Biomea Fusion Inc. (NASDAQ:BMEA), a biotechnology company focused on developing innovative treatments for diabetes and obesity, finds itself at a critical juncture as it navigates regulatory ...

Biomea Fusion Inc. (NASDAQ:BMEA), a biotechnology company focused on developing innovative treatments for diabetes and obesity, finds itself at a critical juncture as it navigates regulatory ...

Analyst Joseph Pantginis of H.C. Wainwright maintained a Buy rating on Biomea Fusion (BMEA – Research Report), retaining the price target ...

Barclays analyst Peter Lawson raised the firm’s price target on Biomea Fusion (BMEA) to $11 from $9 and keeps an Equal Weight rating on ...

H.C. Wainwright has maintained its Buy rating and a $40.00 price target for Biomea Fusion Inc. (NASDAQ: BMEA), a biopharmaceutical company focused on the development of targeted therapies for cancer.

REDWOOD CITY, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to ...

REDWOOD CITY, Calif., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA) (“Biomea” or the “Company”), a clinical stage biopharmaceutical company focused on the discovery and ...